Cullinan Therapeutics (CGEM) Total Current Liabilities: 2020-2023
Historic Total Current Liabilities for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $23.4 million.
- Cullinan Therapeutics' Total Current Liabilities fell 13.55% to $23.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $23.4 million, marking a year-over-year decrease of 13.55%. This contributed to the annual value of $22.5 million for FY2022, which is 91.54% up from last year.
- Cullinan Therapeutics' Total Current Liabilities amounted to $23.4 million in Q3 2023, which was up 19.15% from $19.7 million recorded in Q2 2023.
- Over the past 5 years, Cullinan Therapeutics' Total Current Liabilities peaked at $62.0 million during Q2 2022, and registered a low of $5.7 million during Q2 2021.
- Its 3-year average for Total Current Liabilities is $21.2 million, with a median of $19.7 million in 2023.
- Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 980.18% in 2022, then slumped by 68.28% in 2023.
- Cullinan Therapeutics' Total Current Liabilities (Quarterly) stood at $14.3 million in 2020, then declined by 17.97% to $11.7 million in 2021, then spiked by 91.54% to $22.5 million in 2022, then decreased by 13.55% to $23.4 million in 2023.
- Its last three reported values are $23.4 million in Q3 2023, $19.7 million for Q2 2023, and $26.2 million during Q1 2023.